RxSight, Inc.
RXSTHealthcareNASDAQMedical Devices · Last scanned Sep 9, 2026
Scan Results
Daily timeframePart of the healthcare sector, RxSight, Inc. (RXST) is listed under Medical Devices. At a $268.3M market cap, RxSight, Inc. ranks as a micro-cap company within healthcare. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Market Cap
$268.3M
Beta
1.16
P/E (TTM)
—
P/E (Fwd)
-9.25
EPS (TTM)
$-1.14
EPS (Fwd)
$-0.70
ROE
-17.3%
ROA
-10.4%
Cash
$208.8M
Total Debt
$10.6M
Free CF
-$6.7M
52W Change
-36.4%
Annual Financials
Cash vs Debt
Where RXST stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, RXST finished 7.99% above its 150-day moving average ($6.51) and 7.38% below its 200-day moving average ($7.59). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RXST overbought or oversold?
At the September 3, 2026 close, RXST's RSI(14) was 50.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $208.8M in cash and $10.6M in debt, RXST maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$6.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -17.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $49.0M (2022) to $134.5M (2025), reflecting a 174% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for RxSight, Inc. and its sector.